Skip to content
Drugs Monitor

Drugs Monitor

Tracking drugs for COVID19

Click for Menu
  • Navigate
  • Contact Us
  • Navigate
  • Contact Us
  • (14 May 2020) Corticosteroids- show no good in COVID-19

    May 15, 2020

    Systemic corticosteroids show no benefit in severe and critical COVID-19 patients in Wuhan, China: A retrospective cohort study https://doi.org/10.1101/2020.05.11.20097709 In a retrospective cohort study in Wuhan, corticosteroids were administered in 531 (35.1%) severe and 159 (63.9%) critical patients. Compared to… Continue reading "(14 May 2020) Corticosteroids- show no good in COVID-19"

  • (13 May 2020) Lactoferrin-significantly interfere with SARSCoV-2 replication in vitro at 1 mg/mL

    May 15, 2020

    In Vitro Inhibition of SARS-CoV-2 Infection by Bovine Lactoferrin https://doi.org/10.1101/2020.05.13.093781 Using an antiviral assay based on quantitative reverse transcription-polymerase chain reaction (qRT-PCR), it was found that Bovine lactoferrin (bLf) reduced progeny virus yield by up to ~84,6% in African green… Continue reading "(13 May 2020) Lactoferrin-significantly interfere with SARSCoV-2 replication in vitro at 1 mg/mL"

  • (12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery

    May 13, 2020

    (12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery Early outcomes of tocilizumab in adults hospitalized with severe COVID-19 – 2 SUBTITLE: An initial report from the Vall d’Hebron COVID-19 prospective cohort 3 study. https://doi.org/10.1101/2020.05.07.20094599… Continue reading "(12 May 2020) Tocilizumab- onset to tocilizumab administration may be critical to patient recovery"

  • (12 May 2020) Nafamostat- almost 600-fold more potent than remdesivir in Calu-3 cells

    May 13, 2020

    Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate https://doi.org/10.1101/2020.05.12.090035 Authors identified 24 FDA-approved drugs which exhibited substantial antiviral effect against SARS-CoV-2 in Vero cells. They developed… Continue reading "(12 May 2020) Nafamostat- almost 600-fold more potent than remdesivir in Calu-3 cells"

  • (11 May 2020) Tocilizumab- reduced ICU admissions and deaths

    May 12, 2020

    Tocilizumab therapy reduced intensive care unit admissions and/ormortality in COVID-19 patients https://doi.org/doi:10.1016/j.medmal.2020.05.001 In a retrospective case-control study with a small sample size, death and/or ICU admissions were higher in patients without Tocilizumab (TCZ) than in the TCZ group (72% vs… Continue reading "(11 May 2020) Tocilizumab- reduced ICU admissions and deaths"

  • (11 May 2020) Hydroxychloroquine- not significantly associated with differences in in-hospital mortality

    May 12, 2020

    Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State https://jamanetwork.com/journals/jama/fullarticle/2766117 Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or… Continue reading "(11 May 2020) Hydroxychloroquine- not significantly associated with differences in in-hospital mortality"

  • (11 May 2020) Arbidol – arbidol and Lopinavir/ritonavir combination therapy shows no good

    May 12, 2020

    Observation of the efficacy and safety of lopinavir / ritonavir and abidor in the treatment of new coronavirus pneumonia http://rs.yiigle.com/yufabiao/1193931.htm This paper describes retrospective analysis of the clinical data of 178 patients diagnosed as COVID-19 , and divided into 59… Continue reading "(11 May 2020) Arbidol – arbidol and Lopinavir/ritonavir combination therapy shows no good"

  • (08 May 2020) Remdesivir- Faster recovery rates

    May 11, 2020

    Efficacy of remdesivir in COVID-19 patients with a simulated two-arm controlled study https://doi.org/10.1101/2020.05.02.20088559 Findings from simulated two arm study suggests that Remdesivir treatment results in a 33% significantly higher odds of discharge, a 29% significantly lower risk of death, and… Continue reading "(08 May 2020) Remdesivir- Faster recovery rates"

  • (08 May 2020) Famotidine- associated with reduced risk for death or intubation in COVID 19 patients

    May 11, 2020

    Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study https://doi.org/10.1101/2020.05.01.20086694 In a retrospective study in patients hospitalized with COVID-19  famotidine use was associated with a significantly reduced risk of clinical… Continue reading "(08 May 2020) Famotidine- associated with reduced risk for death or intubation in COVID 19 patients"

  • (08 May 2020)- Hydroxychloroquine- addition of zinc to HCQ, and AZT proves to be more efficacious

    May 11, 2020

    Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients https://doi.org/10.1101/2020.05.02.20080036 In a retrospective observational study to compare hospital outcomes among patients who received hydroxychloroquine and azithromycin plus zinc versus hydroxychloroquine and azithromycin alone, it… Continue reading "(08 May 2020)- Hydroxychloroquine- addition of zinc to HCQ, and AZT proves to be more efficacious"

Posts navigation

Older Posts
Newer Posts

Copyright © 2025 Drugs Monitor. All Rights Reserved. Theme by ilovewp